微针阵列贴片可能降低免疫接种的操作成本:一项蒙特卡洛模拟研究
研究采用蒙特卡洛模拟,量化在常规接种和强化接种模式下,改用微针阵列贴片(MAPs)接种麻疹-风疹、人乳头瘤病毒和伤寒疫苗对操作成本的影响。结果显示,五个用例中每剂次操作成本节省从0.24美元(HPV,1剂瓶,强化接种)到0.61美元(MR,10剂瓶,常规接种),所有用例至少87%概率实现节省。节省可能部分抵消预期的增量制造成本,使转型在预算有限环境中更可行。
要点
- 改用MAPs后,每剂次操作成本节省范围为0.24美元(HPV,1剂瓶,强化接种)至0.61美元(MR,10剂瓶,常规接种)。
- 排除分配的人工成本后,估计节省范围为0.18至0.43美元。
- 所有五个测试用例中,至少87%概率实现成本节省。
核心结论
- 改用MAPs带来的操作成本节省可能至少部分抵消预期的增量制造成本,使转型在预算空间有限的环境中更可行。
- 发展机构应继续投资MAPs技术,若产品上市,可将此证据用于疫苗总价值评估并指导疫苗MAPs实施的投资策略,包括与政策制定者协调。
研究设计与样本
- 蒙特卡洛模拟研究,量化改用MAPs接种麻疹-风疹、人乳头瘤病毒和伤寒疫苗在常规和强化接种模式下的操作成本影响。
- 检查了五个潜在用例。
主要发现
- 每剂次操作成本节省从0.24美元(HPV,1剂瓶,强化接种)到0.61美元(MR,10剂瓶,常规接种)。
- 排除分配的人工成本后,估计节省范围为0.18至0.43美元。
- 由于假设的不确定性,置信区间较宽,但在所有五个测试用例中至少87%概率实现节省。
局限性
- 由于假设的不确定性,置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of microneedle array patches (MAPs) for potential use in immunization is ongoing, but the cost of manufacturing is expected to be higher than that of existing needle-and-syringe vial systems. The potential benefits of MAPs in reaching previously unvaccinated populations have been touted, but affordability, especially in low- and middle-income countries, remains an open question. In this study, we quantify the expected impact on operational costs of switching to MAPs for immunization for measles-rubella, human papilloma virus, and typhoid in both routine and campaign-based delivery modes. We endeavor to make a comprehensive estimate, including the costs of labor, syringes, waste management (i.e., sharps and trash), wastage (unused vaccine), freight and in-country cold chain transportation. We examined five potential use cases and our results show that in total, operational cost savings from a switch to MAPs are expected to range from a low of $0.24 per dose delivered (HPV, 1-dose vial, campaign) up to $0.61 per dose delivered (MR, 10-dose vial, routine). Excluding the allocated cost of labor, the estimated range of cost savings are $0.18 and $0.43, respectively. Confidence intervals are wide, due to the uncertainty in the assumptions, but in all five use cases tested, there was at least an 87 % probability of savings. These results show that operational savings from a switch to MAPs may offset at least part of the expected incremental manufacturing costs, which will make the transition more viable in settings with limited budget space. With this in mind, development agencies should continue to invest in MAPs technology and, if the product does come to market, use this evidence as part of total value of vaccines assessments and to inform investment strategies for implementation of vaccine MAPs, including alignment with policy makers.
引用
- Hagedorn B, Frey K, Scarna T, et al. Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study. Vaccine. 2025. PMID: 39923545. doi:10.1016/j.vaccine.2025.126840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。